NVCT · Nuvectis Pharma, Inc. · Executive Compensation

$20.89 +0.19 (+0.92%) At close · Oct 22

Russell 2000 member Rebalance outlook locked

Market Cap

$680.63M

32.58M

Volume · Oct 22 110.06K Avg daily vol (3M) 205.89K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ron Bentsur	Chairman & CEO	$653,987	$539,539	$1,395,000	—	—	—	$2,588,526
Enrique Poradosu	Chief Scientific & Business Officer	$483,381	$265,860	$837,000	—	—	—	$1,586,241
Shay Shemesh	Chief Development and Operations Officer	$483,381	$265,860	$837,000	—	—	—	$1,586,241

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Enrique Poradosu	Chief Scientific & Business Officer	$468,847	$257,866	$1,088,100	—	—	—	$1,814,813
Shay Shemesh	Chief Development & Operations Officer	$468,847	$257,866	$1,088,100	—	—	—	$1,814,813
Ron Bentsur	President & Chief Executive Officer	$634,323	$523,316	—	—	—	—	$1,157,639

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ron Bentsur	President & Chief Executive Officer	$615,250	$508,875	$1,566,600	—	—	—	$2,690,725
Enrique Poradosu	Chief Scientific & Business Officer	$454,750	$250,750	$857,900	—	—	—	$1,563,400
Shay Shemesh	Chief Development & Operations Officer	$454,750	$250,750	$857,900	—	—	—	$1,563,400

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ron Bentsur	President & Chief Executive Officer	$420,360	$431,250	$842,400	—	—	—	$1,694,010
Enrique Poradosu	Chief Scientific & Business Officer	$349,072	$200,000	$421,200	—	—	—	$970,272
Shay Shemesh	Chief Development & Operations Officer	$329,268	$200,000	$421,200	—	—	—	$950,468

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ron Bentsur	President, Chief Executive Officer and Director	—	—	$384,018	—	—	—	$384,018
Shay Shemesh	Chief Development & Operations Officer	$27,083	—	$192,056	—	—	—	$219,139

Executive changes

Person	Role	Change	Effective	Filed
Juan Sanchez, MD	director	Appointed	2025-09-22	2025-09-25
Ron Bentsur	Class I director	Appointed	2023-06-16	2023-06-16

Leadership

Ron Bentsur CEO, Board Member
James Oliviero Board Member
Juan Sanchez Board Member
Juan Sanchez, MD Board Member
Kenneth Hoberman Board Member
Matthew Kaplan Board Member

Key facts CIK 1875558 CUSIP 67080T108 13F (30d) 10 filings 10 filers Visit website Investor relations